At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IAM Iambic Therapeutics
Not Yet Opened 11-11 16:00:00 EST
15.39
+0.61
+4.09%
盘后15.42
+0.04+0.23%
19:54 EST
High15.85Low13.96Vol364.83K
Open14.87D1 Closing14.78Amplitude12.79%
Mkt Cap729.26MTradable Cap144.23MTotal Shares47.40M
T/O5.42MT/O Rate3.89%Tradable Shares9.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

U.S. casino resort selects BIO-key PortalGuard IAM platform, IBB
TIPRANKS  ·  11-11 21:36
U.S. casino resort selects BIO-key PortalGuard IAM platform, IBB
Iambic Therapeutics Initiated at Buy by Jefferies
Dow Jones  ·  11-10 22:29
Iambic Therapeutics Initiated at Buy by Jefferies
Jefferies Initiates Coverage on Iambic Therapeutics With Buy Rating, $35 Price Target
MT Newswires Live  ·  11-10 20:25
Jefferies Initiates Coverage on Iambic Therapeutics With Buy Rating, $35 Price Target
Iambic Therapeutics: AI-Driven Drug Discovery and Promising Brain-Penetrant Pipeline Support Buy Rating and $35 Price Target
TIPRANKS  ·  11-10 15:55
Iambic Therapeutics: AI-Driven Drug Discovery and Promising Brain-Penetrant Pipeline Support Buy Rating and $35 Price Target
NASDAQ Net Change Percentage Gainers & Losers
Dow Jones  ·  11-10 06:39
NASDAQ Net Change Percentage Gainers & Losers
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results
Benzinga Earnings  ·  11-10 01:12
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results
Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says
MT Newswires Live  ·  11-10 00:37
Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says
BofA Securities Initiates Iambic Therapeutics at Buy With $30 Price Target
MT Newswires Live  ·  11-09 22:54
BofA Securities Initiates Iambic Therapeutics at Buy With $30 Price Target
Iambic CEO Joins AI Drug Discovery Panel at Jefferies Global Healthcare Conference
Reuters  ·  11-09 21:02
Iambic CEO Joins AI Drug Discovery Panel at Jefferies Global Healthcare Conference
Iambic Therapeutics, Inc. : Citigroup Initiates Coverage with Buy Rating; Price Target $22
THOMSON REUTERS  ·  11-09 20:08
Iambic Therapeutics, Inc. : Citigroup Initiates Coverage with Buy Rating; Price Target $22
Iambic Therapeutics Price Target Announced at $30.00/Share by B of a Securities
Dow Jones  ·  11-09 20:07
Iambic Therapeutics Price Target Announced at $30.00/Share by B of a Securities
BofA starts Iambic Therapeutics with a Buy, sees 194% upside
TIPRANKS  ·  11-09 19:36
BofA starts Iambic Therapeutics with a Buy, sees 194% upside
Iambic Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Price Target $22
THOMSON REUTERS  ·  11-09 18:03
Iambic Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Price Target $22
Identity and Biometric Authentication Technologies Provider BIO-key Hosts Q3 Investor Call Friday, November 13 at 10am ET
GlobeNewswire  ·  11-07
Identity and Biometric Authentication Technologies Provider BIO-key Hosts Q3 Investor Call Friday, November 13 at 10am ET
Okta (OKTA) Could Be 10% Below Fair Value As S&P 500 Entry Reshapes Flows
Simply Wall St.  ·  11-07
Okta (OKTA) Could Be 10% Below Fair Value As S&P 500 Entry Reshapes Flows
BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government’s National Security Ecosystem
GlobeNewswire  ·  10-28
BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government’s National Security Ecosystem
Iambic Reports Durable Responses to Iam1363 in Phase 1/1b Cancer Trial
Reuters  ·  10-26
Iambic Reports Durable Responses to Iam1363 in Phase 1/1b Cancer Trial
Iambic Presents Updated Iam1363 Clinical Data at Esmo 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with Her2-Driven Cancers
THOMSON REUTERS  ·  10-26
Iambic Presents Updated Iam1363 Clinical Data at Esmo 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with Her2-Driven Cancers
Iambic Therapeutics - More than Half of Participants at 960 Mg Remain on Study Beyond One Year
THOMSON REUTERS  ·  10-26
Iambic Therapeutics - More than Half of Participants at 960 Mg Remain on Study Beyond One Year
Biotech Is Beating AI in the October IPO Market
Bellwether Stocks Movement  ·  10-25
Biotech Is Beating AI in the October IPO Market

Introduction

Company Name.
Iambic Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company using its Molecular Transformer and proprietary molecular intelligence platform to transform biopharmaceutical discovery. The platform combines large-scale artificial intelligence with automated, scalable chemistry and biology experiments to discover and develop novel medicines.
Issue price:
--